CONCURRENT CHEMORADIOTHERAPY WITH HELICAL TOMOTHERAPY FOR OROPHARYNGEAL CANCER: A PRELIMINARY RESULT

CCUR > College of Kinesiology and Health > Graduate Institute of Sport Coaching Science > journal articles > Item 987654321/20951

Please use this identifier to cite or link to this item: https://irlib.pccu.edu.tw/handle/987654321/20951

Title:	CONCURRENT CHEMORADIOTHERAPY WITH HELICAL TOMOTHERAPY FOR OROPHARYNGEAL CANCER: A PRELIMINARY RESULT
Authors:	Shueng, PW (Shueng, Pei-Wei) Wu, LJ (Wu, Le-Jung) Chen, SY (Chen, Shiou-Yi) Hsiao, CH (Hsiao, Chi-Huang) Tien, HJ (Tien, Hui-Ju) Cheng, PW (Cheng, Po-Wen) Kuo, YS (Kuo, Ying-Shiung) Chen, YJ (Chen, Yu-Jen) Chen, CA (Chen, Chien-An) Hsieh, PY (Hsieh, Pei-Ying) Hsieh, CH (Hsieh, Chen-Hsi)
Contributors:	運教所
Keywords:	Concurrent chemoradiation Helical tomotherapy Intensity-modulated radiotherapy Oropharyngeal cancer
Date:	2010-07
Issue Date:	2011-12-09 14:57:48 (UTC+8)
Abstract:	Purpose: To review the experience with and evaluate the treatment plan for helical tomotherapy for the treatment of oropharyngeal cancer. Methods and Materials: Between November 1, 2006 and January 31, 2009, 10 histologically confirmed oropharyngeal cancer patients were enrolled. All patients received definitive concurrent chemoradiation with helical tomotherapy. The prescription dose to the gross tumor planning target volume, the high-risk subclinical area, and the low-risk subclinical area was 70Gy, 63Gy, and 56Gy, respectively. During radiotherapy, all patients were treated with cisplatin, 30mg/m(2), plus 5-fluorouracil (425mg/m(2))/leucovorin (30mg/m(2)) intravenously weekly. Toxicity of treatment was scored according to the Common Terminology Criteria for Adverse Events, version 3.0. Several parameters, including maximal or median dose to critical organs, uniformity index, and conformal index, were evaluated from dose volume histograms. Results: The mean survival was 18 months (range, 7-22 months). The actuarial overall survival, disease-free survival, locoregional control, and distant metastasis-free rates at 18 months were 67%, 70%, 80%, and 100%, respectively. The average for uniformity index and conformal index was 1.05 and 1.26, respectively. The mean of median dose for right side and left side parotid glands was 23.5 and 23.9Gy, respectively. No Grade 3 toxicity for dermatitis and body weight loss and only one instance of Grade 3 mucositis were noted. Conclusion: Helical tomotherapy achieved encouraging clinical outcomes in patients with oropharyngeal carcinoma. Treatment toxicity was acceptable, even in the setting of concurrent chemotherapy. Long-term follow-up is needed to confirm these preliminary findings. (C) 2010 Elsevier Inc.
Appears in Collections:	[Graduate Institute of Sport Coaching Science ] journal articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	729	View/Open

Loading...